CANDY, a Horizon 2020 project
Many developmental brain diseases co-occur, meaning that if a person has one of those diseases they are quite likely to also have another one. For instance, in autism spectrum disease, the combination of intellectual disability and epilepsy is associated with a reduction in lifespan of about 20 years; and an economic cost that is greater than cancer, stroke, or dementia. Yet, the research spend on neurodevelopmental diseases is less than 1% of the spending on cancer, stroke and dementia.
CANDY’s (Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy) innovation is to test, for the first time, if those diseases and their common mental and bodily co-symptoms, are caused by combinations of common and rare genetic variants and immune activation acting at different ‘sensitive periods’.
The role of Noldus
Noldus will further develop its innovative tools for neuroscience research using animal models to support the research in this project. Specifically it will improve the integration of physiology and behavioral measurements in its EthoVision XT software as well as developing better tracking in EthoVision.
- Radboud University Medical Centre, Nijmegen (Project Leader)
- King's College London
- Pasteur Institute
- University of Basel
- University of Groningen
- University of Gent
- Karolinska Institute
- Assistance Publique des Hôpitaux de Paris
- University of Ulm
- Autism Europe
- Noldus Information Technology
- Birkbeck College, London
This project is funded by the Horizon 2020 research program of the European Union under grant number 847818.